Company Website

Contact Information:

Mike Hoerres, CEO
Cell:  610-730-3626
mhoerres@cernostics.com

Ian Fladoos
Cell: 971-200-0437
ifladoos@cernostics.com

Virtual Exhibit Hall Home

Cernostics applies spatial biology and biologically aware AI and machine learning (ML) to tissue diagnostics, delivering precision testing to patients and gastroenterologists. We applied this technology to develop the TissueCypher® Barrett’s Esophagus Assay, the world’s first precision medicine test that predicts future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE); indicated for BE patients with confirmed intestinal metaplasia graded non-dysplastic (ND), indefinite for dysplasia (IND) or low-grade dysplasia (LGD).
 

TissueCypher® Brochure

Bibliography